Trial Profile
A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women With Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Tamoxifen (Primary) ; Triptorelin (Primary) ; Antineoplastics
- Indications Breast cancer; Ductal carcinoma
- Focus Therapeutic Use
- Acronyms PERCHE
- 12 Jul 2011 Additional trial centre and locations identified as reported by European Clinical Trials Database record.
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record).
- 08 May 2009 Additional lead trial centre identified as reported by Australian New Zealand Clinical Trials Registry record.